Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models
European Journal of Cancer · 2026-11 · 248 · 117698
DOI: 10.1016/j.ejca.2026.117698 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Teh und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Teh, J., Kuhlberg, C., Hegan, P., Smith, K., Pizzano, J., Masson, E., & Wang, X. (2026). Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models. European Journal of Cancer, 248, 117698. https://doi.org/10.1016/j.ejca.2026.117698
Vancouver
Teh J, Kuhlberg C, Hegan P, Smith K, Pizzano J, Masson E, et al. Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models. European Journal of Cancer. 2026;248:117698. doi:10.1016/j.ejca.2026.117698
BibTeX
@article{Teh2026,
author = {Teh, J. and Kuhlberg, C. and Hegan, P. and Smith, K.D. and Pizzano, J. and Masson, E. and Wang, X.},
title = {Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117698},
doi = {10.1016/j.ejca.2026.117698}
}
EUVIMED